Jul 17, 1998

Hematopoietic growth factors for the treatment of aplastic anemia

Current Opinion in Hematology
M Kumar, B P Alter


The use of hematopoietic growth factors, although well established for the management of chemotherapy-induced neutropenia, remains controversial for the treatment of aplastic anemia and inherited bone marrow failure syndromes. The most commonly used factors are granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, and erythropoietin. Newer growth factors such as stem cell factor, thrombopoietin, Flt3 ligand, and interleukins have shown promising results in the laboratory, and some have been used in clinical trials. This article reviews the clinical use of old and new hematopoietic growth factors in acquired and inherited bone marrow failure, and discusses emerging concerns about long term toxicity of these factors.

  • References
  • Citations6


  • We're still populating references for this paper, please check back later.
  • References
  • Citations6


Mentioned in this Paper

Bone Marrow Failure Syndromes
Granulocyte Colony-stimulating Factor Binding
Granulocyte Macrophage Colony-stimulating Factor Receptor Binding Activity
Aplastic Anemia
Hematologic Neoplasms
Epoetin Alfa
FLT3LG gene
Granulocyte Colony-Stimulating Factor

About this Paper

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.